Save time and get answers to complex questions with AI chat
Are there specific stretches to avoid while on lipitor?Tenofovir generic patent?Testosterone enanthate expiration?What's the advised delay for milk post lipitor?Are there income restrictions for lipitor's patient program?
See the DrugPatentWatch profile for Qulipta
AbbVie's Qulipta (atogepant) received approval in South Korea for the preventive treatment of episodic migraine [1]. This marks a significant expansion for the drug's availability in the Asian market.
Qulipta is approved to prevent episodic migraine in adults [1]. Episodic migraine is characterized by a certain frequency of migraine headaches occurring on a limited number of days per month.
Qulipta was approved in South Korea in October 2023 [1].
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pain. By blocking the CGRP receptor, atogepant is thought to help prevent migraine headaches.
Qulipta is also approved and available in the United States and the European Union [1]. Its approval in South Korea expands its global reach.
Qulipta was developed by AbbVie [1]. AbbVie is a biopharmaceutical company with a focus on developing and marketing treatments for a range of serious health conditions.
Other Questions About Qulipta :